Expanding the therapeutic landscape of still's disease: the emerging role of JAK inhibitors
{{output}}
Introduction: Still's disease is a systemic inflammatory disorder characterized by a complex cytokine network involving interleukin (IL)-1, IL‑6, IL‑18 and interferon (IFN)-γ. Although IL‑1 and IL‑6 inhibitors represent the... ...
